Balsalazide: A novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 10, 2009, Pages 1279-1284

  Wiggins, Jon Brendan ^b   Rajapakse, Ramona ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

5 aminosalicylate; Adverse effects; High dose; Mesalamine; Once daily; Prodrug; Remission induction; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BALSALAZIDE; CREATININE; LEUKOTRIENE; LIPOXYGENASE; MERCAPTOPURINE; MESALAZINE; NITROGEN; OLSALAZINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; SALAZOSULFAPYRIDINE; THIOGUANINE DERIVATIVE; TIOGUANINE; UREA; VSL3;

ALOPECIA; ANTIINFLAMMATORY ACTIVITY; BONE MARROW SUPPRESSION; CANCER INCIDENCE; CELL CYCLE PROGRESSION; CLINICAL TRIAL; COCHRANE LIBRARY; COLON CANCER; CONGENITAL MALFORMATION; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HIGH RISK PREGNANCY; HUMAN; IRRITABLE COLON; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LOW BIRTH WEIGHT; MEDLINE; MYOCARDITIS; PANCREATITIS; PERICARDITIS; PNEUMONIA; PREMATURE LABOR; PROSTAGLANDIN SYNTHESIS INHIBITION; RASH; REMISSION; REVIEW; SIDE EFFECT; SPONTANEOUS ABORTION; STILLBIRTH; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UREA NITROGEN BLOOD LEVEL;

CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; GASTROINTESTINAL AGENTS; HUMANS; MESALAMINE; PHENYLHYDRAZINES; PRODRUGS; REMISSION INDUCTION;

EID: 70349395903     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903206996     Document Type: Review

References (31)

1. Ardizzone S. Ulcerative colitis. Orphanet Encylopedia Sept 2003
2. Sood A, Midha V, Sood N, etal. Incidence and prevalence of ulcerative colitis in Punjab, north India. Gut 2003;52(11):1587-1590
3. Orholm M, Binder V, Sørensen TI, et al. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol 2000;35(10):1075-1081 (Pubitemid 30836260)
4. Gumaste V, Sachar DB, Greenstein AJ. Benign and malignant colorectal strictures in ulcerative colitis. Gut 1992;33(7):938-941
5. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006;130(4):1030-1038
6. Svartz N. Salazyopyrin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis B. Therapeutic results in ulcerative colitis C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Med Scand 1942;110:557-590
7. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazo-sulfapyridine. J Pharmacol Exp Ther 1972;181:555-562
8. Van Hees PAM, Bakker JH, Tongreren JHM. Effects of sulfapyridine, 5-aminosalycilic acid, and placebo in patients with idiopathic proctitis: a study to determinethe active therapeutic moiety of sulfasalazine. Gut 1980;21:632-635
9. Hawkey CJ, Boughton-Smith NK, Whittle BJ. Modulation of human colonicarachidonic acid metabolism by sulfasalazine. Dig Dis Sci 1985;30:1161
10. Ligumsky M, Karmeli F, Sharon P, et al. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981;81:444 (Pubitemid 11061542)
11. Miller DK, Gillard JW, Vickers PJ, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990;343:278
12. Stevens C, Lipman M, Fabry S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin 2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther 1995;272:399
13. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003:CD000543
14. Green JR, Swan CH, Gibson JA, et al. Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study.Aliment Pharmacol Ther 2004;19:435-442
15. Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colits. Am J Gastroenterol 2002;97(12):3078-3086 (Pubitemid 35424579)
16. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis. Dig Dis Sci 2009;54(4):712-721 [Epub 6 Aug 2008]
17. Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.Med Sci Monit 2004;10(11):PI126-31. [Epub 26 Oct 2004]
18. Schwab M, Reynders V, Loitsch S, et al. PPAR gamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells
19. Hanauer SB, Smith M. Critical drug appraisal: Olsalazine. Drug Ther Bull 1991;21:57
20. Nikfar S, Rahimi R, Rezaie A, Abdollahi M. Meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and the maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 2009;54(6):1157-1170
21. Woltsche M, Woltseche-Kaur I, Roeger GM, Aberer W. Sulfasalazine-induced extrinsic allergic alveolitis in a patient with psoriatic arthritis. Eur J Med Res 2001;6:495
22. World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalamine-associated interstitial nephritis. Nephrol Dial Transplant 1996;11:614
23. Frandsen NE, Saugmann S, Marcussen N. Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Nephron 2002;92(1):200-202 (Pubitemid 34983894)
24. Tadic M, Grgurevic I, Scukanec-Spoljar M, et al. Acute interstitial nephritis due to mesalazine. Nephrology (Carlton) 2005;10(2):103-105 (Pubitemid 40776265)
25. Netzer P. Diffuse alopecia as side effect of mesalazine therapy in Crohn's disease. Schweiz Med Wochenschr 1995;125(50):2438-2442 (Pubitemid 26013306)
26. Robertson E, Austin D, Jamieson N, Hogg K. Balsalazide-induced myocarditis. Int J Cardiol 2008;130(3):e121-e122
27. Ishikawa N, Imamura T, Nakajima K, et al. Acute pericarditis associated with 5-aminosalicylic acid (5-ASA) treatment for severe active ulcerative colitis. Intern Med 2001;40(9):901-904 (Pubitemid 32958783)
28. Waite RA, Malinowski JM. Possible mesalamine-induced pericarditis: case report and literature review. Pharmacotherapy 2002;22(3):391-394 (Pubitemid 34205177)
29. de Boer NK, Wong DR, Jharap B, etal. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 2007;102(12):2747-2753 [Epub 31 Aug 2007] (Pubitemid 350179331)
30. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008;25(2):271-275 [Epub 4 Dec 2007]
31. Colombel J-F, Brabant G, Gubler M-C, et al. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet 1994;344:620-621